Evidence map›Paper›PMID 40662351›Full record

ReviewAmerican journal of hematology2025

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report.

Hanny Al-Samkari, Raj S Kasthuri, Hans-Jurgen Mager, Jenny Y Zhou, Marcelo M Serra, Bethany T Samuelson-Bannow, Layla N Van Doren, Jay F Piccirillo, Marianne S Clancy, Keith R McCrae and 13 more

Abstract readConsensus StatementReview
In one paragraph

Review in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Hanny Al-SamkariMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-6175-1383
Raj S KasthuriUniversity of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-6672-3082
Hans-Jurgen MagerSt. Antonius Hospital, Nieuwegein, the Netherlands.
Jenny Y ZhouUniversity of California-San Diego, San Diego, California, USA.
Marcelo M SerraHospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Bethany T Samuelson-BannowOregon Health and Science University, Portland, Oregon, USA.
Layla N Van DorenYale University, New Haven, Connecticut, USA.
Jay F PiccirilloWashington University in St. Louis, St. Louis, Missouri, USA.
Marianne S ClancyCure HHT, Monkton, Maryland, USA.
Keith R McCraeCleveland Clinic, Cleveland, Ohio, USA.
Sonia M ThomasResearch Triangle Institute, Durham, North Carolina, USA.
Antoni Riera-MestreHospital Universitari Bellvitge, Barcelona, Spain.
Allyson M PishkoUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sarah SewaralthahabKing Saud University, Riyadh, Saudi Arabia.ORCID 0000-0001-6682-9709
James R GossageAugusta University, Augusta, Georgia, USA.
Vivek N IyerMayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6441-9319
Cedric HermansCatholic University of Louvain, Brussels, Belgium.
Adrienne HammillUniversity of Cincinnati, Cincinnati, Ohio, USA.
Ingrid WinshipUniversity of Melbourne, Melbourne, Australia.
Meir Mei-ZahavTel Aviv University, Tel Aviv, Israel.
Annette von DrygalskiUniversity of California-San Diego, San Diego, California, USA.
Scott OlitskyCure HHT, Monkton, Maryland, USA.
Marie E FaughnanUniversity of Toronto, Toronto, Canada.

Funding

Oregon BIRCWH: Scholars in Women's Health Research Across the LifespanK12AR084221 · NIAMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI LESLIE MYATT · 2023 to 2026
$2.2M
NIAMS NIH HHS K12 AR084221
6 · The paper itself

Abstract

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease-modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT-specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician-investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. SEARCH STRATEGY AND SELECTION CRITERIA: Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4-13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.

Indexed as

HemorrhageTelangiectasia, Hereditary HemorrhagicTerminology as TopicHumansSeverity of Illness Indexanemiaangiogenesisbleedingepistaxisgastrointestinal bleedingHereditary hemorrhagic telangiectasiaHHTiron deficiencyOsler‐Weber‐Rendu

Identifiers

PMID40662351
PMCPMC12417758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.